Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM
Original Article from The New England Journal of Medicine — Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Original Article from The New England Journal of Medicine — Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived prod…
The world’s most influential people in health have made fresh discoveries, dreamed up novel treatments, and pioneered global victories over disease.
Abstract. Oncogenesis and progression of pancreatic ductal adenocarcinoma (PDAC) is driven by complex interactions between the neoplastic component and the tumor microenvironment (TME), which includes…
Efficient communication and care coordination are critical for high-quality patient care in ambulatory oncology settings. Electronic huddles, where the cancer team connects in a virtual…
The commission estimates that banning noncompete clauses will lower health care costs by up to $194 billion in the next 10 years May 3, 2024…
The International Lung Cancer Survivorship Conference (ILCSC) is a virtual educational conference for people with lung cancer, caregivers, and advocates.
Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived prod…
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Exclusive: Donna Ockenden, who led a damning review into failings at Shrewsbury maternity services, described the support as “a house of cards” as she urged…
RAHWAY, N.J., May 01, 2024–Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer